Journal of Clinical Oncology, Vol 12, 1561-1571, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer

S Welt, CR Divgi, N Kemeny, RD Finn, AM Scott, M Graham, JS Germain, EC Richards, SM Larson and HF Oettgen
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

PURPOSE: A phase I/II study was designed to determine the maximum- tolerated dose (MTD) of iodine 131-labeled monoclonal antibody (mAb) A33 (131I-mAb A33) administered intravenously, its limiting organ toxicity, and its radioisotope retention in tumors, and to develop preliminary evidence of antitumor activity. PATIENTS AND METHODS: Patients (N = 23) with colorectal cancer who had failed to respond to conventional chemotherapy but had not received prior radiotherapy were treated with escalating doses of 131I-mAb A33. Three or more patients were entered at each dose level, starting at 30 mCi/m2, with increments of 15 mCi/m2 to a maximal dose of 90 mCi/m2. Radiolabeling was performed to maintain a specific activity of 30 mCi/m2/4 mg mAb A33 (projected maximum, 15 mCi/mg). Patients were under strict isolation precautions until whole-body radiation levels decreased to less than 5 mrem/h at 1 m. Serial radioimmunoscintigrams were performed in some cases for up to 3 weeks after 131I-mAb A33 administration. RESULTS: All 20 patients with radiologic evidence of disease showed localization of radioisotope to sites of disease. Two patients with elevated carcinoembryonic antigen (CEA) levels and negative radiologic tests did not have positive antibody scans. One patient with a small-bowel cancer also had a negative antibody scan. The major toxicity was hematologic and was more pronounced in patients with compromised bone marrow due to prior chemotherapy. Of five patients who received 78 to 84 mCi/m2 131I- mAb A33, one had grade 3 and one grade 4 toxicity; of six patients treated with 86 to 94 mCi/m2 131I-mAb A33, two had grade 4 and one grade 1 toxicity. The MTD was determined to be 75 mCi/m2 in these heavily pretreated patients. Although the isotope showed variable uptake in the normal bowel, gastrointestinal symptoms were mild (n = 8) or absent. No major responses were observed; however, three patients had evidence of mixed responses, and CEA levels decreased in two patients without clinical or radiologic measurable disease. Immunoreactivity of radiolabeled mAb A33 decreased at the highest dose levels in preparations in which specific activity exceeded 18 mCi/mg. CONCLUSION: The A33 antigen appears to be a promising target for radioimmunotherapy of colon cancer. The modest antitumor activity of 131I-mAb A33 in heavily pretreated patients is encouraging because of its lack of toxicity in the bowel, the only antigen-positive normal tissue.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Ychou, D. Azria, C. Menkarios, P. Faurous, F. Quenet, B. Saint-Aubert, P. Rouanet, M. Pelegrin, C. Bascoul-Mollevi, D. Guerreau, et al. Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3487 - 3493. [Abstract] [Full Text] [PDF]

				A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake Clin. Cancer Res., July 1, 2005; 11(13): 4810 - 4817. [Abstract] [Full Text] [PDF]

				G. Chong, F. T. Lee, W. Hopkins, N. Tebbutt, J. S. Cebon, A. J. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, P. U, et al. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4818 - 4826. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and C. Divgi Current Status of Therapy of Solid Tumors J. Nucl. Med., January 1, 2005; 46(1_suppl): 141S - 150S. [Abstract] [Full Text] [PDF]

				J. Y. C. Wong, S. Shibata, L. E. Williams, C. S. Kwok, A. Liu, D. Z. Chu, D. M. Yamauchi, S. Wilczynski, D. N. Ikle, A. M. Wu, et al. A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5842 - 5852. [Abstract] [Full Text] [PDF]

				P. K. E. Borjesson, E. J. Postema, J. C. Roos, D. R. Colnot, H. A. M. Marres, M. H. van Schie, G. Stehle, R. de Bree, G. B. Snow, W. J. G. Oyen, et al. Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2003; 9(10): 3961s - 3972s. [Abstract] [Full Text]

				S. Welt, G. Ritter, C. Williams Jr., L. S. Cohen, M. John, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny Phase I Study of Anticolon Cancer Humanized Antibody A33 Clin. Cancer Res., April 1, 2003; 9(4): 1338 - 1346. [Abstract] [Full Text] [PDF]

				S. Welt, G. Ritter, C. Williams Jr., L. S. Cohen, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny Preliminary Report of a Phase I Study of Combination Chemotherapy and Humanized A33 Antibody Immunotherapy in Patients with Advanced Colorectal Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1347 - 1353. [Abstract] [Full Text] [PDF]

				C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo Immunotherapy of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 181 - 200. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]

				G. Ritter, L. S. Cohen, C. Williams Jr., E. C. Richards, L. J. Old, and S. Welt Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33 Cancer Res., September 1, 2001; 61(18): 6851 - 6859. [Abstract] [Full Text] [PDF]

				E. C. Barendswaard, J. L. Humm, J. A. O'Donoghue, G. Sgouros, R. D. Finn, A. M. Scott, S. M. Larson, and S. Welt Relative Therapeutic Efficacy of 125I- and 131I-Labeled Monoclonal Antibody A33 in a Human Colon Cancer Xenograft J. Nucl. Med., August 1, 2001; 42(8): 1251 - 1256. [Abstract] [Full Text] [PDF]

				F. T. Lee, C. Hall, A. Rigopoulos, J. Zweit, K. Pathmaraj, G. J. O’Kevfe, F. E. Smyth, S. Welt, L. J. Old, and A. M. Scott Immuno-PET of Human Colon Xenograft- Bearing BALB/c Nude Mice Using 124I-CDR-Grafted Humanized A33 Monoclonal Antibody J. Nucl. Med., May 1, 2001; 42(5): 764 - 769. [Abstract] [Full Text]

				J. Y. C. Wong, D. Z. Chu, D. M. Yamauchi, L. E. Williams, A. Liu, S. Wilczynski, A. M. Wu, J. E. Shively, J. H. Doroshow, and A. A. Raubitschek A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies Clin. Cancer Res., October 1, 2000; 6(10): 3855 - 3863. [Abstract] [Full Text]

				C. N. Johnstone, N. C. Tebbutt, H. E. Abud, S. J. White, K. L. Stenvers, N. E. Hall, S. H. Cody, R. H. Whitehead, B. Catimel, E. C. Nice, et al. Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells Am J Physiol Gastrointest Liver Physiol, September 1, 2000; 279(3): G500 - G510. [Abstract] [Full Text] [PDF]

				C. Rader, G. Ritter, S. Nathan, M. Elia, I. Gout, A. A. Jungbluth, L. S. Cohen, S. Welt, L. J. Old, and C. F. Barbas III The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies J. Biol. Chem., April 28, 2000; 275(18): 13668 - 13676. [Abstract] [Full Text] [PDF]

				K. A. Foon, J. Yannelli, and M. Bhattacharya-Chatterjee Colorectal Cancer as a Model for Immunotherapy Clin. Cancer Res., February 1, 1999; 5(2): 225 - 236. [Full Text] [PDF]

				J. K. Heath, S. J. White, C. N. Johnstone, B. Catimel, R. J. Simpson, R. L. Moritz, G.-F. Tu, H. Ji, R. H. Whitehead, L. C. Groenen, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily PNAS, January 21, 1997; 94(2): 469 - 474. [Abstract] [Full Text] [PDF]

				B. Catimel, G. Ritter, S. Welt, L.J. Old, L. Cohen, M.A. Nerrie, S.J. White, J.K. Heath, B. Demediuk, T. Domagala, et al. Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium J. Biol. Chem., October 11, 1996; 271(41): 25664 - 25670. [Abstract] [Full Text] [PDF]